Skip to main content

Table 2 Treatment recommendations and hospitalization policies for imported, uncomplicated falciparum malaria in selected European countries

From: Therapy of uncomplicated falciparum malaria in Europe: MALTHER – a prospective observational multicentre study

 

First-line

Hospitalization policy

treatment

Recommendations (R) or standard practice (SP)

Belgium

Atovaquone-proguanilArtemether-lumefantrine

SP : hospitalization (ambulatory treatment possible under certain conditions)

 

Quinine + cycline

 

France

Atovaquone-proguanil Artemether-lumefantrine

R : Ambulatory treatment possible on the basis of specific clinical and biological parameters

Germany

Atovaquone-proguanil Artemether-lumefantrine

R : hospitalization recommended until treatment completed and patient parasite-free

 

Mefloquine

 

Italy

Atovaquone-proguanil

SP : hospitalization (ambulatory treatment possible under certain conditions)

 

Mefloquine

 

Spain

Quinine + cycline or clindamycin Atovaquone-proguanil

SP: hospitalization (ambulatory treatment possible under certain conditions)

Switzerland

Artemether-lumefantrine Atovaquone-proguanil

SP: hospitalization (ambulatory treatment possible under certain conditions)

United Kingdom

Atovaquone-proguanil

R : Systematically, at least 24 h

 

Artemether-lumefantrine

 
 

Quinine + cyclines

 

The Netherlands

Atovaquone-proguanil Artemether-lumefantrine

SP: hospitalization (ambulatory treatment possible under certain conditions)

 

Quinine + cyclines

 
 

Chloroquine*

 
  1. *selected areas with known chloroquine-sensitive P. falciparum, e.g. Central America.